150 results on '"KISH, JONATHAN"'
Search Results
2. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
3. Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer
4. Real-World Dosing Patterns of Ruxolitinib in Patients With Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea
5. Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA
6. Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
7. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs
8. Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States
9. Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
10. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States
11. Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events
12. Coping with Vicarious Trauma in the Aftermath of a Natural Disaster
13. Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer.
14. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.
15. Surgical Resection Preferences and Perceptions among Medical Oncologists Treating Liver Metastases from Colorectal Cancer
16. Human-Associated Methicillin-Resistant Staphylococcus aureus from a Subtropical Recreational Marine Beach
17. Impacts of the 2010 Haitian Earthquake in the Diaspora : Findings from Little Haiti, Miami, FL
18. Traditional and molecular analyses for fecal indicator bacteria in non-point source subtropical recreational marine waters
19. Quantitative evaluation of enterococci and Bacteroidales released by adults and toddlers in marine water
20. Preventing heat-related morbidity and mortality: New approaches in a changing climate
21. Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study.
22. Earlier presentation and application of curative treatments in hepatocellular carcinoma
23. Ethnicity predicts metabolic syndrome after liver transplant
24. Real-World Investigation of Spleen, Symptom, and Hematologic Response in Patients with Myelofibrosis Treated with First-Line Ruxolitinib
25. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
26. 925 REDUCING REAL-WORLD HEALTHCARE RESOURCE UTILIZATION FOR PATIENTS WITH DIABETIC GASTROPARESIS (DGP) TREATED WITH METOCLOPRAMIDE NASAL SPRAY VERSUS ORAL METOCLOPRAMIDE
27. Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma.
28. The BEACHES Study: health effects and exposures from non-point source microbial contaminants in subtropical recreational marine waters
29. Impact of Augmented Intelligence on Utilization of Palliative Care Services in a Real-World Oncology Setting.
30. Economic and clinical impact of a novel, light-based, at-home antiviral treatment on mild-to-moderate COVID-19.
31. Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A US Real-World Retrospective Cohort Study
32. Real-World Observational Study of Outcomes for Acute Myeloid Leukemia (AML) in Patients Treated with Glasdegib or Venetoclax in US Community Oncology Practices
33. Shedding of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus from adult and pediatric bathers in marine waters
34. Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States
35. Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experiment.
36. Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma.
37. Comparative Effectiveness of Palliative Chemotherapy in Metastatic Breast Cancer: A Real‐World Evidence Analysis.
38. Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents.
39. Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer.
40. Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy.
41. Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data
42. Real-World Utilization of Midostaurin Among Patients with Acute Myeloid Leukemia (AML)
43. Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea
44. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
45. Acute myeloid leukemia in the elderly: what constitutes treatment value?
46. Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax (VEN) or Chemotherapy (CT)/Chemoimmunotherapy (CIT)
47. Cost-Effectiveness Comparison between Ibrutinib, Chemotherapy, and Chemoimmunotherapy in Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
48. Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting.
49. Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies.
50. Adverse events during chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies (HM): Real-world, US patient experience.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.